HK1143559A1 - Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydro-1-napthalenamine and its formamide - Google Patents

Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydro-1-napthalenamine and its formamide

Info

Publication number
HK1143559A1
HK1143559A1 HK10110208.5A HK10110208A HK1143559A1 HK 1143559 A1 HK1143559 A1 HK 1143559A1 HK 10110208 A HK10110208 A HK 10110208A HK 1143559 A1 HK1143559 A1 HK 1143559A1
Authority
HK
Hong Kong
Prior art keywords
napthalenamine
dichlorophenyl
tetrahydro
formamide
trans
Prior art date
Application number
HK10110208.5A
Other languages
English (en)
Inventor
Thomas P Jerussi
Qun Kevin Fang
Mark Currie
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of HK1143559A1 publication Critical patent/HK1143559A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
HK10110208.5A 2002-09-16 2010-10-29 Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydro-1-napthalenamine and its formamide HK1143559A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41130502P 2002-09-16 2002-09-16
US41130402P 2002-09-16 2002-09-16

Publications (1)

Publication Number Publication Date
HK1143559A1 true HK1143559A1 (en) 2011-01-07

Family

ID=31998027

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10110208.5A HK1143559A1 (en) 2002-09-16 2010-10-29 Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydro-1-napthalenamine and its formamide

Country Status (16)

Country Link
US (6) US7087785B2 (zh)
EP (1) EP1542961B1 (zh)
JP (1) JP4610336B2 (zh)
KR (2) KR101067045B1 (zh)
CN (1) CN101712626B (zh)
AU (1) AU2003272460B2 (zh)
BR (1) BRPI0314377B8 (zh)
CA (1) CA2498152C (zh)
DK (1) DK1542961T3 (zh)
ES (1) ES2431519T3 (zh)
HK (1) HK1143559A1 (zh)
IL (1) IL167319A (zh)
MX (1) MXPA05002700A (zh)
NZ (1) NZ538741A (zh)
PT (1) PT1542961E (zh)
WO (1) WO2004024669A1 (zh)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1542961T3 (da) 2002-09-16 2013-11-04 Sepracor Inc Trans-4-(3,4-dichlorphenyl)-1,2,3,4-tetrahydro-1-napthalenamin til anvendelse til behandling af cns-forstyrrelser
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
AU2004305563C1 (en) * 2003-12-11 2011-07-07 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
KR20060128976A (ko) 2003-12-29 2006-12-14 세프라코 아이엔시. 피롤 및 피라졸 디에이에이오 억제제
US20060199739A1 (en) * 2005-03-02 2006-09-07 Olav Messerschmidt Limonene-containing herbicide compositions, herbicide concentrate formulations and methods for making and using same
CN101553217A (zh) * 2005-07-06 2009-10-07 塞普拉科公司 艾司佐匹克隆与反式4－(3,4－二氯苯基)－1,2,3,4－四氢－n－甲基－1－萘胺或反式4－(3,4－二氯苯基)－1,2,3,4－四氢－1－萘胺的组合以及治疗绝经期和心境障碍、焦虑症和认知障碍的方法
JP2009522721A (ja) * 2005-12-29 2009-06-11 ユーティーシー パワー コーポレイション ガス輸送式燃料電池冷媒の循環
AU2006335174B2 (en) * 2006-01-06 2012-09-06 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
CA2636324C (en) 2006-01-06 2012-03-20 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
AU2013211500B2 (en) * 2006-03-31 2016-08-04 Sepracor Inc Preparation of chiral amides and amines
EP2013835B1 (en) * 2006-03-31 2015-11-04 Sunovion Pharmaceuticals Inc. Preparation of chiral amides and amines
BRPI0712744A2 (pt) * 2006-05-31 2012-09-25 Sepracor Inc método para tratar um distúrbio da dor em um humano
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
JP5765884B2 (ja) * 2006-09-25 2015-08-19 アーチャー−ダニエルズ−ミッドランド カンパニー 超吸収性表面処理カルボキシアルキル化多糖類及びその製造方法
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
FR2909376A1 (fr) * 2006-11-30 2008-06-06 Cerep Sa Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
US20090099248A1 (en) * 2007-01-18 2009-04-16 Sepracor Inc. Inhibitors of d-amino acid oxidase
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
EP2154962A4 (en) 2007-05-31 2012-08-15 Sepracor Inc PHENYL-SUBSTITUTED CYCLOALKYLAMINE AS A MONOAMINE RECOVERY INHIBITOR
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
CA2759180A1 (en) * 2009-05-13 2010-11-18 Sunovion Pharmaceuticals Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
ES2531312T3 (es) * 2009-12-04 2015-03-12 Sunovion Pharmaceuticals Inc Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos
US9220712B2 (en) 2011-05-19 2015-12-29 Gilrose Pharmaceuticals, Llc Pharmaceutical intervention and method for treating an apraxia of speech in children
US9682073B2 (en) 2011-05-19 2017-06-20 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder gait and limb impairments treatment
US10085414B2 (en) 2011-05-19 2018-10-02 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder speech, gait and limb impairments treatment
US20140163070A1 (en) 2012-05-17 2014-06-12 Bruce Roseman Treatment for cerebral palsy impaired speech in children
WO2012158892A2 (en) 2011-05-19 2012-11-22 Bruce Roseman A method of treating apraxia of speech in children
US8883815B2 (en) 2011-05-19 2014-11-11 Gilrose Pharmaceuticals, Llc Treatment for cerebral palsy impaired speech in children
EP3143000A4 (en) * 2014-05-13 2017-12-13 Sunovion Pharmaceuticals Inc. Dosage of dasotraline and method for treatment of adhd
CN106660936A (zh) * 2014-05-13 2017-05-10 赛诺维信制药公司 用于治疗adhd的方法和达斯曲林(dasotraline)组合物
WO2016046669A2 (en) * 2014-09-27 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of depression and neurological diseases
JP2021512057A (ja) * 2018-01-19 2021-05-13 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 経口製剤
US20210386689A1 (en) 2018-10-31 2021-12-16 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders
EP3800178A1 (en) 2019-10-01 2021-04-07 Moehs Ibérica, S.L. Preparation of enamide intermediate for the synthesis of dasotraline

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59497B2 (ja) * 1979-11-01 1984-01-07 フアイザ−・インコ−ポレ−テツド トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体
US4556676A (en) 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4981870A (en) 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5778986A (en) * 1997-08-05 1998-07-14 Davis; Floyd A. Device to remove divots
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
DK1542961T3 (da) * 2002-09-16 2013-11-04 Sepracor Inc Trans-4-(3,4-dichlorphenyl)-1,2,3,4-tetrahydro-1-napthalenamin til anvendelse til behandling af cns-forstyrrelser

Also Published As

Publication number Publication date
CA2498152A1 (en) 2004-03-25
US7423179B2 (en) 2008-09-09
US20060216799A1 (en) 2006-09-28
AU2003272460A2 (en) 2004-04-30
AU2003272460B2 (en) 2009-12-17
IL167319A (en) 2013-10-31
US20080280993A1 (en) 2008-11-13
US7105699B2 (en) 2006-09-12
EP1542961A1 (en) 2005-06-22
CN101712626B (zh) 2013-11-20
KR101067045B1 (ko) 2011-09-22
DK1542961T3 (da) 2013-11-04
CN101712626A (zh) 2010-05-26
PT1542961E (pt) 2013-11-05
KR101165549B1 (ko) 2012-07-19
US20060014982A1 (en) 2006-01-19
BRPI0314377B8 (pt) 2021-05-25
BRPI0314377B1 (pt) 2020-11-24
KR20110091043A (ko) 2011-08-10
US7589237B2 (en) 2009-09-15
BR0314377A (pt) 2005-07-19
AU2003272460A1 (en) 2004-04-30
US7087785B2 (en) 2006-08-08
JP2005539068A (ja) 2005-12-22
US20040092605A1 (en) 2004-05-13
WO2004024669A1 (en) 2004-03-25
CA2498152C (en) 2012-01-10
KR20050084552A (ko) 2005-08-26
ES2431519T3 (es) 2013-11-26
JP4610336B2 (ja) 2011-01-12
EP1542961B1 (en) 2013-09-11
MXPA05002700A (es) 2005-09-08
NZ538741A (en) 2007-01-26
US7790772B2 (en) 2010-09-07
US20060128993A1 (en) 2006-06-15
US20090292026A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
HK1143559A1 (en) Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydro-1-napthalenamine and its formamide
NO20034996D0 (no) Nye arylsusfonamidforbindelser for behandlingen av fedme, type II diabetesog CNS-forstyrrelser
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
IL158631A0 (en) 4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
AP2334A (en) Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders.
HK1070361A1 (en) 5-sulphanyl-4h-1,2,4-triazole derivatives and their use to treat disorders associated with somatostatine
NO20041176L (no) Nye 4,5-dihydro- 1H-pyrazolderivater med CB1-antagonistisk aktivitet
AU2003243420A8 (en) 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
PL370163A1 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
ZA200507806B (en) 2-phenoxy- and 2-enysulfomamide derivatives with CCR3 antagonistic acitivity for the treatment of asthma and other inflammatory or immunolgical disorders
EP1904066A4 (en) COMBINATIONS OF ESZOPICLONE AND TRANS 4- (3,4-DICHLOROPHENYL) -1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPHTHALENAMINE OR TRANS 4- (3,4-DICHLOROPHENYL) -1,2, 3,4-TETRAHYDRO-1-NAPHTHALENAMINE, AND METHODS FOR TREATING MENOPAUSE AND DISORDERS OF MOOD, ANXIETY AND COGNITIVE DISORDERS
IL165051A0 (en) New compounds useful for the treatment of obesity,type II diabetes and cns disorders
IL159347A0 (en) Arylamines for the treatment of conditions associated with gsk-3
HK1077732A1 (en) Lifting mechanism and health care equipment that incorporates the lifting mechanism
PL1708790T3 (pl) Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
PL368130A1 (en) 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases
NO20052699D0 (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
EP1499309A4 (en) PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES
ZA200306171B (en) (Diazolo-pyridinyl)-pyrimidines for use in treatment of CNS disorders and diabetes.
NO20034232D0 (no) Anvendelse av glukokortikoid-reseptor-spesifikke antagonister ved behandling av stresslidelser
EP1581206A4 (en) TREATMENT OF INFLAMMATORY DISEASES WITH 2,3-BENZODIAZEPINES
IL158704A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HK1041880A1 (en) Compounds and methods for treatment of asthma, allergy and inflammatory disorders.
IL195441A0 (en) Use of trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine and its formamide in the preparation of medicaments for the treatment of pain disorders
EP1379236A4 (en) TREATMENT OF TICS, TREMORS AND RELATED DISORDERS

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220911